Keld-Erik Byg, Torkell Ellingsen, Jimmi Wied, Michella Peiris, Simon Joel Lowater, Tobias Sejbaek, Jakob Grauslund
{"title":"光学相干断层扫描显示结节病伴眼系统受累患者视网膜厚度增加:一项横断面研究。","authors":"Keld-Erik Byg, Torkell Ellingsen, Jimmi Wied, Michella Peiris, Simon Joel Lowater, Tobias Sejbaek, Jakob Grauslund","doi":"10.1007/s00296-025-05818-2","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigates the thickness of retinal structures in patients with neurosarcoidosis (NS) and ocular sarcoidosis (OS). We compared the central macular thickness (CMT), retinal thickness (RT), central nerve fiber layer (RNFL) thickness, and ganglion cell layer (GCL) thickness using optical coherence tomography. In a cross-sectional study, we categorized 97 sarcoidosis patients (185 eyes) into four groups: patients without ocular or central nervous system sarcoidosis (Non-Ocular/Non-CNS, n = 53), patients with OS (Ocular, n = 13), patients with NS (CNS, n = 16), and patients with combined OS and NS (Ocular/CNS, n = 15). The mean age was 51 (14) years. We found no overall difference between the groups in the CMT (p = 0.3), RT (p = 0.9), RNFL (p = 0.3), and GCL measurements (p = 0.9). Only in patients with a disease duration of more than five years, the CMT was significantly thicker in the Ocular group (278 μm, p < 0.001), the CNS group (267 μm, p = 0.04), and the Ocular/CNS group (268 μm, p = 0.04), compared to the Non-Ocular/Non-CNS group (249 μm). The RT was significantly thicker in the Ocular group (296 μm, p = 0.008) and the Ocular/CNS group (291 μm, p = 0.03) compared to the Non-Ocular/Non-CNS group (283 μm). In the RNFL measurements, the Ocular group (33.7 μm, p = 0.002) was thicker than the Non-ocular/Non-CNS group (29.1 μm). We found an increased retinal thickness in patients with ocular sarcoidosis and long disease duration.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 3","pages":"66"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868241/pdf/","citationCount":"0","resultStr":"{\"title\":\"Increased retinal thickness in sarcoidosis patients with ocular system involvement visualized with optical coherence tomography: a cross-sectional study.\",\"authors\":\"Keld-Erik Byg, Torkell Ellingsen, Jimmi Wied, Michella Peiris, Simon Joel Lowater, Tobias Sejbaek, Jakob Grauslund\",\"doi\":\"10.1007/s00296-025-05818-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study investigates the thickness of retinal structures in patients with neurosarcoidosis (NS) and ocular sarcoidosis (OS). We compared the central macular thickness (CMT), retinal thickness (RT), central nerve fiber layer (RNFL) thickness, and ganglion cell layer (GCL) thickness using optical coherence tomography. In a cross-sectional study, we categorized 97 sarcoidosis patients (185 eyes) into four groups: patients without ocular or central nervous system sarcoidosis (Non-Ocular/Non-CNS, n = 53), patients with OS (Ocular, n = 13), patients with NS (CNS, n = 16), and patients with combined OS and NS (Ocular/CNS, n = 15). The mean age was 51 (14) years. We found no overall difference between the groups in the CMT (p = 0.3), RT (p = 0.9), RNFL (p = 0.3), and GCL measurements (p = 0.9). Only in patients with a disease duration of more than five years, the CMT was significantly thicker in the Ocular group (278 μm, p < 0.001), the CNS group (267 μm, p = 0.04), and the Ocular/CNS group (268 μm, p = 0.04), compared to the Non-Ocular/Non-CNS group (249 μm). The RT was significantly thicker in the Ocular group (296 μm, p = 0.008) and the Ocular/CNS group (291 μm, p = 0.03) compared to the Non-Ocular/Non-CNS group (283 μm). In the RNFL measurements, the Ocular group (33.7 μm, p = 0.002) was thicker than the Non-ocular/Non-CNS group (29.1 μm). We found an increased retinal thickness in patients with ocular sarcoidosis and long disease duration.</p>\",\"PeriodicalId\":21322,\"journal\":{\"name\":\"Rheumatology International\",\"volume\":\"45 3\",\"pages\":\"66\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868241/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00296-025-05818-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05818-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
本研究探讨了神经结节病(NS)和眼结节病(OS)患者视网膜结构的厚度。我们使用光学相干断层扫描比较了中央黄斑厚度(CMT)、视网膜厚度(RT)、中枢神经纤维层(RNFL)厚度和神经节细胞层(GCL)厚度。在一项横断面研究中,我们将97例结节病患者(185只眼)分为四组:无眼部或中枢神经系统结节病患者(Non-Ocular/Non-CNS, n = 53), OS患者(ocular, n = 13), NS患者(CNS, n = 16), OS和NS合并患者(ocular /CNS, n = 15)。平均年龄51(14)岁。我们发现两组间在CMT (p = 0.3)、RT (p = 0.9)、RNFL (p = 0.3)和GCL测量(p = 0.9)方面没有总体差异。仅在病程超过5年的患者中,眼部组的CMT明显变厚(278 μm, p
Increased retinal thickness in sarcoidosis patients with ocular system involvement visualized with optical coherence tomography: a cross-sectional study.
This study investigates the thickness of retinal structures in patients with neurosarcoidosis (NS) and ocular sarcoidosis (OS). We compared the central macular thickness (CMT), retinal thickness (RT), central nerve fiber layer (RNFL) thickness, and ganglion cell layer (GCL) thickness using optical coherence tomography. In a cross-sectional study, we categorized 97 sarcoidosis patients (185 eyes) into four groups: patients without ocular or central nervous system sarcoidosis (Non-Ocular/Non-CNS, n = 53), patients with OS (Ocular, n = 13), patients with NS (CNS, n = 16), and patients with combined OS and NS (Ocular/CNS, n = 15). The mean age was 51 (14) years. We found no overall difference between the groups in the CMT (p = 0.3), RT (p = 0.9), RNFL (p = 0.3), and GCL measurements (p = 0.9). Only in patients with a disease duration of more than five years, the CMT was significantly thicker in the Ocular group (278 μm, p < 0.001), the CNS group (267 μm, p = 0.04), and the Ocular/CNS group (268 μm, p = 0.04), compared to the Non-Ocular/Non-CNS group (249 μm). The RT was significantly thicker in the Ocular group (296 μm, p = 0.008) and the Ocular/CNS group (291 μm, p = 0.03) compared to the Non-Ocular/Non-CNS group (283 μm). In the RNFL measurements, the Ocular group (33.7 μm, p = 0.002) was thicker than the Non-ocular/Non-CNS group (29.1 μm). We found an increased retinal thickness in patients with ocular sarcoidosis and long disease duration.
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.